TAZVERIK: payments to doctors
Payments that named TAZVERIK as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.6M
- Providers
- 4,056
- Transactions
- 9,146
- Average per transaction
- $281
The per-transaction average — $281 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,056 providers the average total is $633, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $1,280,823 | 49.9% |
| Epizyme, Inc., | $1,233,958 | 48.1% |
| Epizyme, Inc. | $49,401 | 1.9% |
| Ipsen Bioscience Inc. | $2,600 | 0.1% |